PCRX
Pacira BioSciences, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 89 | +2 | 30.85M | $781.81M | +7 | −4 |
| Q1 2026 | 89 | -5 | 30.76M | $694.94M | +2 | −7 |
| Q4 2025 | 94 | -1 | 36.25M | $938.05M | — | −1 |
| Q3 2025 | 19 | +1 | 24.74M | $637.46M | +2 | −1 |
| Q2 2025 | 15 | 0 | 22.66M | $541.65M | +1 | −1 |
| Q1 2025 | 12 | -3 | 10.29M | $255.59M | — | −3 |
| Q4 2024 | 15 | +1 | 11.71M | $220.69M | +1 | — |
| Q3 2024 | 13 | 0 | 9.23M | $138.98M | +1 | −1 |
| Q2 2024 | 13 | — | 6.89M | $197.00M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 2.07M | — | $59.11M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.09M | — | $31.17M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.09M | — | $31.17M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Marshall Wace ✦ | 971.14K | — | $27.78M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 971.14K | — | $27.78M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Baillie Gifford ✦ | 806.10K | — | $23.06M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Baillie Gifford ✦ | 806.10K | — | $23.06M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Baillie Gifford ✦ | 806.10K | — | $23.06M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Baillie Gifford ✦ | 806.10K | — | $23.06M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 487.13K | — | $13.94M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 487.13K | — | $13.94M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 487.13K | — | $13.94M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 487.13K | — | $13.94M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Wellington Management ✦ | 487.13K | — | $13.94M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 480.43K | — | $13.75M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 480.43K | — | $13.75M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 300.06K | — | $8.58M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 249.14K | — | $7.13M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 249.14K | — | $7.13M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Norges Bank ✦ (passive) | 210.06K | — | $6.01M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 76.02K | — | $2.18M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 67.61K | — | $1.93M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 67.61K | — | $1.93M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Arrowstreet Capital ✦ | 53.41K | — | $1.53M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 28.93K | — | $827,630 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 3 holders, 13.02M shares, $12.57M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.